Market Place
Sourcing Support
All News #Library
Rare Diseases
Quince Reports Positive Ph 3 eDSP Data in Ataxia-Telangiectasia
29 Jan 2026 //
BUSINESSWIRE
Quince Therapeutics Reveals Long-Term eDSP Safety Data
28 Jan 2026 //
BUSINESSWIRE
Quince Therapeutics Completes Phase 3 NEAT Trial
15 Dec 2025 //
BUSINESSWIRE
Quince Therapeutics Publishes Edsp Use In Early Clinical Studies
10 Dec 2025 //
BUSINESSWIRE
Quince Therapeutics Announces Positive iDSMB Review for eDSP
10 Nov 2025 //
BUSINESS WIRE
Quince Therapeutics Showcases Ataxia-Telangiectasia Walking Data
09 Oct 2025 //
PHARMIWEB
Quince Publishes eDSP PK Modeling Study In CPT Journal
25 Sep 2025 //
BUSINESSWIRE
Quince Therapeutics Exceeds 75% Enrollment in Phase 3 NEAT Trial
03 Jun 2025 //
BUSINESSWIRE
Quince’s EryDex Long-Term Safety Data Publish in Neurology Journal
27 Jan 2025 //
BUSINESSWIRE
FDA fast tracks Quince Therapeutics’ rare ataxia drug EryDex
04 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
Quince buys a rare disease biotech
24 Jul 2023 //
ENDPTS
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.